TITLE

Candesartan reduces incidence of retinopathy in study

AUTHOR(S)
Nale, Pat; Williams, George A.
PUB. DATE
December 2008
SOURCE
Ocular Surgery News Europe/Asia-Pacific Edition;Dec2008, Vol. 19 Issue 12, p20
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on results of a study on the effectiveness of angiotensin-receptor blocker candesartan in reducing the incidence of retinopathy in type 1 diabetes. According to the study, the risk of retinopathy progression was insignificantly reduced by 13 percent in treated patients compared with patients on placebo. Disease regression was increased by 34 percent in treated patients. Even after adjustment for baseline covariates and after further attenuation adjusting for systolic blood pressure, the effect of the drug remained significant.
ACCESSION #
35376227

 

Related Articles

  • Role of Inflammation in the Pathogenesis of Diabetic Retinopathy. Abu El-Asrar, Ahmed M. // Middle East African Journal of Ophthalmology;Jan-Mar2012, Vol. 19 Issue 1, p70 

    Diabetic retinopathy (DR) remains a major cause of worldwide preventable blindness. The microvasculature of the retina responds to hyperglycemia through a number of biochemical changes, including activation of protein kinase C, increased advanced glycation end products formation, polyol pathway,...

  • The Treatment of Diabetic Retinopathy: A View for the Internist. Raskin, Philip; Arauz-Pacheco, Carlos // Annals of Internal Medicine;8/1/92, Vol. 117 Issue 3, p226 

    Presents a study that investigated the status of surgical and medical therapy for diabetic retinopathy. Pathogenesis and epidemiology of the disease; Information on the surgical treatment of diabetic retinopathy; Discussion on a study on the use of antiplatelet therapy in the treatment of the...

  • A Matter Of Vision. Stuckey, Heather L. // Diabetes Forecast;Mar1996, Vol. 49 Issue 3, p100 

    Recounts the experience of a diabetic patient when she was surgically treated for advanced proliferative diabetic retinopathy. Feelings of the patient when first diagnosed with disease; Apprehension during the surgery; Lessons learned from the experience.

  • Lucentis' Phase III Data Show DME Improvements. Wall, Tom // BioWorld Today;3/11/2011, Vol. 22 Issue 48, p2 

    The article reports on the first of two Phase III studies of Lucentis ranibizumab injection for diabetic macular edema (DME) released by Genentech. According to Genentech, the initial study reached its main endpoint when 44.8 percent of the patients under Lucentis therapy were able to read at...

  • Interobserver Agreement in Detecting Spectral-Domain Optical Coherence Tomography Features of Diabetic Macular Edema. Heng, Ling Zhi; Pefianaki, Maria; Hykin, Philip; Patel, Praveen J. // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Purpose: To evaluate interobserver agreement for the detection of spectral-domain optical coherence tomography (SDOCT) features of diabetic macular edema (DME). Method: Cross-sectional study in which 2 retinal specialists evaluated SDOCT scans from eyes receiving treatment for DME. Scans from...

  • (Pro)renin Receptor-Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation. Satofuka, Shingo; Ichihara, Atsuhiro; Nagai, Norihiro; Noda, Kousuke; Ozawa, Yoko; Fukamizu, Akiyoshi; Tsubota, Kazuo; Itoh, Hiroshi; Oike, Yuichi; Ishida, Susumu // Diabetes;Jul2009, Vol. 58 Issue 7, p1625 

    OBJECTIVE--The term "receptor-associated prorenin system" (RAPS) refers to the pathogenic mechanisms whereby prorenin binding to its receptor dually activates the tissue renin-angiotensin system (RAS) and RAS-independent intracellular signaling via the receptor. The aim of the present study was...

  • Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*). MASSIN, PASCALE; BANDELLO, FRANCESCO; GARWEG, JUSTUS G.; HANSEN, LUTZ L.; HARDING, SIMON P.; LARSEN, MICHAEL; MITCHELL, PAUL; SHARP, DIANNE; WOLF-SCHNURRBUSCH, U. E. K.; GEKKIEVA, MARGARITA; WEICHSELBERGER, ANDREAS; WOLF, SEBASTIAN // Diabetes Care;Nov2010, Vol. 33 Issue 11, p2399 

    OBJECTIVE -- The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center. RESEARCH DESIGN AND...

  • Intravitreal Kenalog Injection May Slow Diabetic Retinopathy Progression.  // Review of Optometry;Feb2010, Vol. 147 Issue 2, p8 

    The article reports on the result of a study which determined the efficacy of intravitreal injections of triamcinolone acetonide on the progression of diabetic retinopathy. It includes randomly selected 840 eyes with macular edema to receive laser photocoagulation, 1mg injections or 4mg...

  • Effect of intravitreal bevacizumab injection on visual acuity in patients with proliferative diabetic retinopathy. Ali Bahoo, Muhammad Luqman; Karamat, Beenish; Mirza, Khurram Azam; Farooq, Mian Usman // Pakistan Journal of Medical Sciences;Oct2011, Vol. 27 Issue 5, p1060 

    Objective: To determine the effect of intravitreal bevacizumab injection on visual acuity in patients with proliferative diabetic retinopathy. Methodology: Seventy eyes of 52 patients of proliferative diabetic retinopathy with visual acuity of ≤6/36 were selected from 26-02-2009 to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics